

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tirzepatide for managing overweight and obesity [ID6179]

Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<u>Company</u> <ul style="list-style-type: none"> Eli Lilly (tirzepatide) <u>Patient/carer groups</u> <ul style="list-style-type: none"> All About Obesity BEAT Black Health Agency for Equality British Obesity Society Diabetes UK Diabetes Research and Wellness Independent Diabetes Trust National Centre for Eating Disorders National Obesity Forum Obesity Empowerment Network Obesity Health Alliance Obesity UK Overeaters Anonymous South Asian Health Foundation Specialised Healthcare Alliance Weight Concern <u>Healthcare professional groups</u> <ul style="list-style-type: none"> Association of British Clinical Diabetologists Association for the Study of Obesity British Dietetic Association British Heart Foundation British Nutrition Foundation British Obesity and Metabolic Surgery Society Faculty of Public Health Nutrition Society Obesity Management Association Primary Care Diabetes Society Royal College of General Practitioners Royal College of Nursing 	<u>General</u> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Diabetes UK Cymru Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <u>Possible comparator companies</u> <ul style="list-style-type: none"> A A H Pharmaceuticals (orlistat) Alissa Healthcare Research (orlistat) Almus Pharmaceuticals (orlistat) Crescent Pharma (orlistat) Medihealth (Northern) (orlistat) Neon Healthcare (orlistat) Novo Nordisk (liraglutide, semaglutide) Sigma Pharmaceuticals (orlistat) Teva UK (orlistat) <u>Relevant research groups</u> <ul style="list-style-type: none"> Cochrane Metabolic & Endocrine Disorders Group Cochrane Public Health Group

Final stakeholder list for the evaluation of tirzepatide for managing overweight and obesity [ID6179]

Issue date: June 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 2

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health and Social Care NHS England 	<ul style="list-style-type: none"> Cochrane UK Genomics England MRC Clinical Trials Unit National Institute for Health Research Obesity Institute <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.